FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,276 letters match. Newest first.

  1. Meamo

    Meamo's website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers, FDA says.

    High risk
  2. MJS Medicals

    FDA warned South Korea's MJS Medicals for selling unapproved, misbranded botulinum toxin ("Innotox") to U.S. consumers online.

    High risk
  3. Derma Solution

    FDA warned Derma Solution for selling unapproved, misbranded injectable Botulax botulinum toxin drugs online to U.S. consumers.

    High risk
  4. Glowface

    Glowface's website sells unapproved, misbranded injectable Botulax botulinum toxin drugs to U.S. consumers, FDA says.

    High risk
  5. Apotex Inc.

    FDA cited Apotex's Richmond Hill sterile plant for failed investigations and aseptic contamination risks, prompting recalls.

    High risk
  6. Liebel-Flarsheim Company LLC

    Liebel-Flarsheim's Raleigh, NC sterile drug plant failed to investigate microbial and endotoxin test failures and let cleanrooms and equipment fall into disrepair.

    High risk
  7. onlineotcmeds.com

    FDA warned onlineotcmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and Schedule II stimulants to U.S. consumers online.

    High risk
  8. Scientific Protein Laboratories, LLC

    FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.

    High risk
  9. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  10. The Tranzonic Companies/Innocore Sales & Marketing Inc.

    FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.

    High risk
  11. Acme United Corporation

    Acme United Corporation made antiseptic wipes with contaminated water and released sterile drugs without sterility testing.

    High risk
  12. Foshan Yiying Hygiene Products Co., Ltd.

    Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.

    High risk
  13. Melcare Biomedical Pty Ltd

    Australia's Melcare Biomedical sells Optimel Manuka+ eye gel and drops in the US as unapproved drugs with honey as an active ingredient.

    High risk
  14. www.usmedschoice.com

    FDA warned www.usmedschoice.com for selling unapproved and misbranded opioids, benzodiazepines, and stimulants online without prescriptions.

    High risk
  15. Guangxi Yulin Pharmaceutical Group Co. Ltd.

    FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.

    High risk
  16. BRS Analytical Services, LLC

    BRS Analytical Services, LLC made sterile OTC drugs in an unsuitable aseptic facility and recalled them over sterility assurance.

    High risk
  17. Health and Natural Beauty USA Corp.

    FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.

    High risk
  18. Naturich Cosmetique Labs

    FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.

    High risk
  19. Creative Essences, Inc.

    FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

    High risk
  20. Dixon Investments Inc. dba ARI

    FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.

    High risk
  21. Persōn & Covey, Inc.

    FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.

    High risk
  22. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk
  23. Ralph A. DeFronzo, M.D.

    FDA warns Dr. Ralph A. DeFronzo for enrolling ineligible subjects and failing to promptly report study changes to the IRB.

    High risk
  24. Stellalife, Inc.

    FDA told Stellalife its homeopathic oral care gels and rinses are unapproved new drugs sold without FDA approval.

    High risk
  25. Media Networks Sydney Pty. Limited

    FDA says Australia's Media Networks Sydney failed to answer drug records requests for OTC Combantrin Chocolate Squares.

    High risk
  26. Chengdu Brilliant Biopharmaceutical Co., Ltd.

    FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.

    High risk
  27. motionpharmacy.com

    FDA warns motionpharmacy.com over selling unapproved and misbranded prescription drugs online.

    High risk
  28. PureRawz

    FDA warns PureRawz its tianeptine products are unapproved new drugs sold with drug claims.

    High risk
  29. cheaptrustedpharmacy.com

    cheaptrustedpharmacy.com sells unapproved, misbranded prescription drugs to U.S. consumers online, FDA warns.

    High risk
  30. Janssen Vaccines Corp., A Johnson & Johnson Company

    FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.

    Medium
  31. Columbia Cosmetics Manufacturing Inc.

    Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.

    High risk
  32. Get.Fit.Medical, LLC dba Get.Fit.Medical

    FDA warned Get.Fit.Medical that its website sold compounded sildenafil, tadalafil, semaglutide and tirzepatide with false 'generic' claims.

    High risk
  33. FWD Care, Inc. dba FWD

    FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.

    Medium
  34. Expert Aesthetics

    FDA warned Expert Aesthetics over website claims that its compounded semaglutide and tirzepatide are generic Ozempic and Mounjaro.

    Low
  35. Dermacare LLC dba BlueChew

    FDA warned BlueChew over website claims that its compounded sildenafil and tadalafil are the same as Viagra and Cialis.

    High risk
  36. Healthy Living Clinic

    FDA warned Healthy Living Clinic that its website misbrands compounded semaglutide by comparing it to Wegovy, Ozempic, and Rybelsus.

    Low
  37. Hims & Hers Health, Inc. dba Hers

    FDA warned Hims & Hers (Hers) that its website misleads consumers about compounded semaglutide by implying it is the same as approved Ozempic and Wegovy.

    Medium
  38. Amazing Meds

    FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.

    High risk
  39. GenLabMeds

    GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.

    High risk
  40. FitRX, LLC dba Zealthy

    FDA warns Zealthy over website claims that compounded semaglutide is the same as Wegovy and Ozempic.

    Medium
  41. Lean Dreams LLC dba LeanDreams

    FDA warned LeanDreams over website claims that compounded semaglutide and tirzepatide match FDA-approved Ozempic, Wegovy, Mounjaro and Zepbound.

    Low
  42. ybycmeds

    FDA warns ybycmeds over website claims that compounded semaglutide and tirzepatide are similar to approved brand-name drugs.

    Medium
  43. iVisitDoc, Inc. dba iVisitDoc

    FDA warns iVisitDoc over website claims that compounded semaglutide is equivalent to Wegovy and Ozempic, calling the drugs misbranded.

    Medium
  44. Try Nova

    FDA warned Try Nova that its website’s compounded semaglutide claim "Same active ingredient as Wegovy & Ozempic" is false or misleading.

    Low
  45. Lovely Meds, Inc. dba Lovely Meds

    FDA cited Lovely Meds for misleading website claims that compounded semaglutide and tirzepatide are the same as FDA-approved drugs.

    Low
  46. The HCG Institute

    FDA warns The HCG Institute over misleading claims for compounded semaglutide sold online.

    High risk
  47. Vitals RX

    FDA warned telehealth seller Vitals RX that its website falsely implies compounded semaglutide and tirzepatide are the approved drug Ozempic.

    Medium
  48. Tuyo Health, Inc. dba Tuyo Health

    FDA warns Tuyo Health over misleading claims for compounded semaglutide and tirzepatide sold online.

    Medium
  49. Las Villas Health Care LLC dba Villas Health

    FDA warned Villas Health over website claims for compounded semaglutide and sildenafil, calling the drugs misbranded and unapproved.

    High risk
  50. Lyfe Rx

    Lyfe Rx offered compounded semaglutide and tirzepatide online with false 'clinically proven weight loss' claims, FDA says.

    Low